Register for a live broadcast to learn more about TRODELVY (sacituzumab govitecan-hziy) with Dr. Hope S. Rugo

General Discussions

To Know or Not to Know: Data in Metastatic Breast Cancer

By Patricia Jakel, MN, RN, AOCN
PUBLISHED WEDNESDAY, DECEMBER 31, 1969


With the constant advancements in metastatic breast cancer, there are many situations where there may not be clear data on long-term outcomes or quality of life for certain drugs, said Patricia Jakel, MN, RN, AOCN.

Jakel is an advanced practice nurse at UCLA's solid tumor program, co-editor in chief of Oncology Nursing News, and a breast cancer survivor.

Transcription

We're leapfrogging so fast with metastatic breast cancer that we sometimes don't have data to tell you what it's going to be like in 4 or 5 years. That oftentimes is difficult for data-driven people. Other people, like myself, I didn't really want to know the data because I'm not a big data person. I want to know well what's the quality of life when you're on these medications? Am I going to be able to work? Am I going to be able to exercise? Exercise was important to me. So it really depends on what's important to you at that point in your life.
Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.